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A B S T R A C T
Although cancer was originally considered a disease driven only by genetic mutations, it has now been proven
that it is also an epigenetic disease driven by DNA hypermethylation-associated silencing of tumor suppressor
genes and aberrant histone modifications. Very recently, a third component has emerged: the so-called epi-
transcriptome understood as the chemical modifications of RNA that regulate and alter the activity of RNA
molecules. In this regard, the study of genetic and epigenetic disruption of the RNA-modifying proteins is gaining
momentum in advancing our understanding of cancer biology. Furthermore, the development of epitran-
scriptomic anticancer drugs could lead to new promising and unexpected therapeutic strategies for oncology in
the coming years.
1. Introduction
Cancer was fundamentally considered a genetic disease. However, it
is not until most recently that it has also been recognized as an epige-
netic and metabolic disease, beyond genetics. The impairment of me-
tabolic programs in cancer has a deep effect on epigenetic regulation,
which contributes to genomic instability and alters the epigenetic
landscape. Improved understanding of the common tumor-promoting
metabolic preferent pathways in cancer progression and of metabolic
plasticity in cancer drug resistance, have revealed promising ther-
apeutic targets based on tumor metabolic and epigenetic vulnerabilities
rather than the extreme variation of the genetic profiles of tumours.
A limited repertoire of epigenetic modifications in DNA is docu-
mented compared to epitranscriptomic modifications. DNA methylation
is the best-characterized epigenetic mechanism. It mainly occurs on
cytosines (5 mC, 5hmC, 5 fC, and 5caC) and is the most abundant and
stable epigenetic mark in eukaryotes that is closely involved in gene
regulation.
In contrast, much less is known about the more than 170 distinct
RNA chemical modifications, their roles, and their respective RNA-
modifying proteins that deposit, remove, and recognize them on the
specific RNA species found. Indeed, the study of the RNA epigenome or
epitranscriptome is just the tip of the iceberg [1] and is starting to
emerge, revealing the mechanisms and functions of RNA modification
biology. In particular, RNA modifications have a broad spectrum of
functions in RNA metabolism, including RNA processing [2], splicing
[3,4], polyadenylation, editing [5], structure [6], stability [7], locali-
zation, translation initiation [8], and gene expression regulation [9].
In the past two decades, remarkable advances in high throughput
technologies, such as the Next-Generation Sequencing (NGS) methods,
genome-wide DNA methylation profiling, proteomics, and metabo-
lomics, along with the era of collaborations and interdisciplinary re-
search teams, have enabled us to achieve a more complete under-
standing of tumor biology and to accelerate biomedical research. Thus,
the integration of cancer multi-omics approaches and datasets is likely
to reflect the biological complexity of cancer biology (Fig. 1). Moreover,
the discovery of the epitranscriptome revealed another omic layer and a
new dimension of gene expression regulation, the study of which is
beginning to elucidate the complex orchestration of the gene expression
programs and the roles of RNA modification pathways in cancer.
Within the last ten years, the field of traditional cancer drug dis-
covery, which has mainly focused on oncogenic drivers, has brought
about major advances in clinical oncology. However, in many cases,
patients ultimately acquire cancer drug resistance, which often arises as
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a consequence of the epigenetic and metabolic plasticity of cancer cells
[10]. Therefore, because little is currently known about the develop-
ment of epigenetic cancer drugs, the RNA-modifying proteins could
represent a promising new class of anticancer target for drug discovery,
to better leverage advances in cancer treatment and to improve patient
outcomes.
2. Proteins involved in RNA chemical modifications
The epitranscriptome is characterized by over a hundred chemical
marks on cellular RNAs that regulate the activities of the transcripts
[11]. These RNA modifications are recognized at specific regions of a
transcript by “readers” and are catalyzed by effectors capable of de-
positing and removing them [11]. Collectively, these proteins are
known as RNA-modifying proteins (RMPs), in a close analogy to epi-
genetic regulation mediated by modifications of DNA, histones, and
chromatin, known as chromatin-modifying proteins. RMPs fall into
three groups: “writers”, the enzymes that deposit RNA chemical marks;
“erasers”, the enzymes that remove them; and “readers”, the proteins
that selectively recognize and bind to specific RNA chemical mod-
ifications. Dysregulation and mutations in RMPs have been associated
with human diseases [12], including neurological diseases, cancer,
genetic birth defects, obesity, and infertility. The first RMP identified as
being involved in human disease was the m6A “eraser” FTO, which was
associated with obesity and cancer.
The deposition of chemical modifications onto RNAs is catalyzed by
multiprotein writer complexes. The first methyltransferase-like
(METTL) gene family member, METTL3, was identified in 1994 [13].
METTL3 form a multicomponent methyltransferase complex that
transfers a methyl group at the N6 position of the adenosine base (m6A)
in specific RNA transcripts (mRNAs and ncRNAs). Methylation is one of
the most common modifications in RNA. RNA methyltransferase en-
zymes catalyze methylation via a methyl synthase mechanism using the
ubiquitous methyl donor S-adenosylmethionine (SAM) as a source and
cofactor to methylate RNA. They are a well-known and diverse group of
“writers” involved in human diseases such as METTL3 in lymphoid
malignancies and NSUN5 in glioblastoma. Recent studies suggest,
however, that mRNA methylation might require synergy among the
member proteins of the methyltransferase complexes for efficient RNA
methylation, which could vary depending on the cellular phenotypes
and the disease processes in play [14].
Many enzymes have been identified as being RNA methyl-
transferases, such as METTL, NSUN, TRMT, MePCE, BCDIN3D,
ALKBH8, RNMT, and TRMT family of proteins. Examples of non-me-
thyltransferases are DKC1, NAT10, and TRIT1, which are “writers” for
RNA modifications pseudouridine (Ψ), N4-acetylcytosine, and N6-iso-
pentenyladenosine, respectively.
Fat mass and obesity-associated protein (FTO) was the first RNA
“eraser” discovered in 2011. It was found to demethylate m6A in DNA
and RNA, and the methylation at m6A in RNA proved to be reversible
and dynamic, leading to the coining of the term epitranscriptome.
Another m6A RNA demethylase was subsequently identified, the alpha-
ketoglutarate-dependent dioxygenase known as alkb homolog 5
(ALKBH5). In particular, both FTO and ALKBH5 enzymes belong to the
same ALKBH family.
Proteins that produce a cellular response by recognizing RNA
modifications are known as RNA “readers”. The YTH domain proteins
are the most well-studied family of RNA “readers” [15]. They bind to
m6A-modified mRNA and fulfill several functions: YTHDC1 binds to
nascent m6A-methylated mRNA in the nucleus, participating in exon
selection during splicing events; YTHDF1 binds to m6A-modified mRNA
in the cytoplasm, increasing translation efficiency independent of the
m7G cap; on the other hand, YTHDF2 recruits the CCR4-NOT complex
to the bound mRNA, increasing rate of decay. Other m6A “readers” are
the IGF2BP family of proteins, which increase the stability of the m6A-
methylated mRNAs [16]. And m5C “reader” ALYREF recognizes m5C
modification in mRNA, promoting its nucleus-to-cytosol export [17].
Unidirectional and nonreversible RNA-editing mechanisms alter the
Fig. 1. Linking “omic” approaches to cancer: seeking a comprehensive picture of tumor biology. Multi-omics from the genome, epigenome, transcriptome, epi-
transcriptome, proteome, and epiproteome.
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Table 1
RNA modifications and RNA-modifying proteins related to cancer development.Legend: W: Writer, E: Eraser, R: Reader, TS: Tumor suppressor, Onc: Oncogene.
Nt. RNA Modification RNA-modifying proteins Site-specific position & RNA specie Associated Cancer Cancer Ref.
A m1A TRMT6 (W) A58 tRNA-Met Gastrointestinal Cancer (Onc) [46]
mRNA Gastrointestinal Cancer (Onc) [46]
TRMT10C (W) A9 tRNA mitchondrial Gastrointestinal Cancer (Onc) [46]
TRMT61A (W) A58 tRNA Gastrointestinal Cancer (Onc) [46]
mRNA Gastrointestinal Cancer (Onc) [46]
ALKBH1 (E) A58 tRNA Cervix Cancer (Onc) [47]
ALKBH3 (E) mRNA (5′UTR near Start Codon) Pancreatic Cancer (Onc) [48]
Breast Cancer (Onc) [49]
Ovarian Cancer (Onc) [49]
A58 tRNA Cervix Cancer (Onc) [50]
A ms2i6A CDK5RAP1 (W) A37 tRNA mitochondrial Breast Cancer (Onc) [51]
Melanoma (Onc) [52]
A i6A TRIT1 (W) A37 tRNA-SelenoCys Lung Cancer (TS) [53]
Gastric Cancer [54]
A m6A METTL3 (W) mRNA (5′UTR, ORF, 3′UTR) Endometrial Cancer (TS) [24]
Glioblastoma (TS) [33]
Breast Cancer (Onc) [55]
Hepatocarcinoma (Onc) [56]
AML (Onc) [33]
FTO (E) mRNA Glioblastoma (Onc) [57]
Cervix Cancer (Onc) [58]
AML (Onc) [38]
Melanoma (Onc) [59]
Gastric Cancer (Onc) [60]
Breast Cancer (Onc) [30]
ALKBH5 (E) mRNA Pancreatic Cancer (TS) [61]
AML (TS) [32]
Glioblastoma (Onc) [62]
Breast Cancer (Onc) [63]
YTHDC2 (R) mRNA Colorectal Cancer (Onc) [64]
YTHDF2 (R) mRNA Pancreatic Cancer (Dual Effect) [65]
Hepatocarcinoma (Onc) [66]
Prostate Cancer (Onc) [67]
C m3C METTL6 (W) C32 tRNA-Ser Breast Cancer (Onc) [68]
Lung Cancer (Onc) [69]
METTL8 (W) mRNA Hepatocarcinoma (TS) [70]
ALKBH1 (E) C32 tRNA Hepatocarcinoma (Onc) [70]
C34 tRNA mitochondrial Hepatocarcinoma (Onc) [70]
Cervix Cancer (Onc) [47]
ALKBH3 (E) C32, C47 tRNA Cervix Cancer [50]
C m5C NSUN1 (W) C4447 rRNA-28S Leukemia (Onc) [71]
NSUN2 (W) C34, C47, C48, C49, C50 tRNA Ovarian Cancer (TS) [72]
Skin Cancer (TS) [73]
mRNA Squamous-Cell Carcinoma (Onc) [74]
Breast Cancer (Onc) [75]
Bladder Cancer (Onc) [25]
NSUN3 (W) C34 tRNA mitochondrial Non-Small Cell Lung Cancer [76]
NSUN4 (W) C841 rRNA-12S Breast and Prostate Cancer [77]
NSUN5 (W) C3782 rRNA-28S Glioblastoma (TS) [26]
DNMT2 (W) C38 tRNA-Asp Colorectal Cancer (Onc) [78]
C ac4C NAT10 (W) C12 tRNA-Leu/Ser Ovaric Cancer [79]
mRNA (ORF) Hepatocarcinoma [80]
C1337 rRNA-18S Colorectal Cancer (Onc) [81]
G m7Gpp(pN) RNMT (W) mRNA (5′Cap) Breast Cancer (Onc) [82]
NUDT16 (E) mRNA (5′Cap) T-ALL (TS) [2]
G m7G METTL1 (W) G46 tRNA Hepatocarcinoma [83]
miRNA Lung Cancer (TS) [84]
BUD23 (W) G1639 rRNA-18S Metastasis in p53+ tumours (Onc) [85]
G m2,2G TRMT1 (W) G26 tRNA Breast Cancer [86]
G m2G TRMT11 (W) G6, G10, G26 tRNA Prostate Cancer [87]
G Q TGT (W) G34 tRNA-Asn/Asp/His/Tyr T-Cell Lymphoma (TS) [88]
Colon Cancer (Onc) [89]
G yW (and derivatives) TYW2 (W) G37 tRNA-Phe Head and Neck (Onc) [90]
Breast Cancer (Onc) [91]
U m5U TRMT2A (W) U54 (tRNA) Breast Cancer (TS) [92]
U ncm5U ELP3 (W) U34 tRNA-Lys/Gln/Glu Breast Cancer (Onc) [93]
U mcm5U ELP3 (W) U34 tRNA-Lys/Gln/Glu Breast Cancer (Onc) [93]
ALKBH8 (W)
U mcm5s2U CTU1 (W) U34 tRNA-Lys/Gln/Glu Breast Cancer (Onc) [93]
Melanoma (Onc) [40]
CTU2 (W) Breast Cancer (Onc) [93]
Melanoma (Onc) [40]
ELP3 (W) Breast Cancer (Onc) [93]
ALKBH8 (W) Breast Cancer (Onc) [93]
(continued on next page)
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RNA sequences and lead to changes in the transcriptome brought about
by RNA-editing enzymes that regulate metabolism. Adenosine-to-in-
osine (A-to-I) editing, along with pseudouridine and ribose 2′-O-me-
thylation, is one of the most common types of RNA modification in
eukaryotes. The conversion of A-to-I is a unidirectional and irreversible
modification catalyzed by adenosine deaminases such as ADAR and
ADAT family proteins that act on mRNAs and tRNAs, respectively. A-to-
I editing has several cellular implications, such as altering enzymatic
protein activity, alternative splicing and cellular response to stress
conditions as well as regulating the innate immune response and
modulating miRNA biogenesis and function. Another kind of RNA
editing, known as C-to-U editing, is catalyzed by the cytidine deaminase
family of proteins known as AADs (AID/APOBEC).
In summary, the dynamic RNA changes brought about by RNA-
modifying enzymes modulate RNA metabolism and functions, thereby
affecting cell fate and differentiation. These enzymes involve complex
mechanisms and metabolic conditions. As an example, methyl-
transferase reactions consume 12–13 molecules of ATP (Fig. 3). Thus,
the high-energy cost of RNA modification pathways indicates that the
RNA-modifying enzymes have important consequences in overall cel-
lular metabolism, suggesting that they have important roles in the
progression of several types of human cancer.
3. RNA-modifying proteins and their respective chemical marks in
cancer
One of the major discoveries of clinical importance in the field of
epitranscriptomics is the identification of coding and noncoding RNA
modifications linked to several human diseases, including cancer [18].
Many RNA-modifying enzymes with crucial roles in human diseases
have been identified over the past decade, attracting interest from
cancer researchers. The time is ripe to face the challenge of under-
standing and characterizing the mechanisms and roles of RNA-mod-
ifying enzymes and their respective RNA modifications.
3.1. RNA modifications linked to cancer
Due to technological limitations, studies performed over recent
decades have primarily focused on RNA chemical modifications present
in the most highly abundant RNA species (tRNA and rRNA). At present,
technological advances in mass spectrometry, transcriptome-wide
analysis of RNA modifications by NGS technologies, and antibody im-
munoprecipitation have enabled the study of several RNA modifications
that are present in low-abundance RNA species, such as mRNAs and
miRNAs [19].
The first RNA modifications were identified almost 70 years ago.
Pseudouridine (Ψ) was the first to be found in RNA, particularly in
yeast tRNA [20]. Pseudouridine is the most abundant nucleotide
modification in rRNA and tRNA and is also present in mammalian and
yeast mRNA. It plays a role in RNA folding and secondary structure,
stability and translation, and was the first RNA modification to be
linked to cancer [21].
As mentioned earlier, over 170 RNA chemical modifications thus far
have been found in different organisms, and over 60 RNA modifications
have been identified in eukaryotes (Modomics database: http://
modomics.genesilico.pl/) [22]. The role of RNA modifications is not
only determined by the incorporation, removal or recognition of RNA
marks at selective sites on specific nucleotides of a variety RNA mole-
cules, but also by specific cellular settings, such as cell-context-specific
and cell-state-dependent patterns. RNA modifications influence a dis-
tinct and broad spectrum of functions in RNA metabolism, including
RNA stability, splicing, processing, editing, structure, localization,
Table 1 (continued)
Nt. RNA Modification RNA-modifying proteins Site-specific position & RNA specie Associated Cancer Cancer Ref.
U D DUS2 (W) U20 tRNA Lung Cancer [94]
U Ψ DKC1 (W) rRNA (~36 sites in 18S, ~57 sites in 28S) X-Linked Dyskeratosis congenita [95]
Prostate Cancer (Onc) [96]
Breast Cancer (Onc) [97]
Hepatocarcinoma (Onc) [98]
Lung Cancer (Onc) [99]
Others Nm Fibrillarin (W) rRNA (41 sites in 18S, 67 sites in 28S.
U14 and G75 in 5.8S)
Breast Cancer (Onc) [100]
HENMT1 (W) piRNA Testicular tumours [101]
Others m(pN) BCDIN3D (W) miRNA (5′Cap) Breast Cancer (Onc) [102]
MePCE (W) 7SK RNA Breast Cancer (Onc) [103]
Editing A-to-I ADAR1 (W) mRNA Hepatocarcinoma (Onc) [27]
Colorectal Cancer (Onc) [104]
Gastric Cancer (Onc) [105]
Esophageal Cancer (Onc) [28]
Glioblastoma (Onc) [106]
Lung Cancer (Onc) [5]
miRNA Leukemia (Onc) [107]
ADAR2 (W) mRNA Gastric Cancer (Onc) [105]
Editing C-to-U APOBEC1 (W) mRNA Hepatocarcinoma (Onc) [108]
APOBEC3G (W) mRNA Hepatocarcinoma (Onc) [109]
RNA modifications: m1A: 1-methyladenosine, ms2i6A: 2-methylthio-N6-isopentenyl-adenosine, i6A: N6-isopentenyladenosine, m6A: N6-methyladenosine, m3C: 3-
methylcytosine, m5C: 5-methylcytosine, ac4C: N4-acetylcytosine, m7Gpp(pN): 7-methylguanosine cap, m7G: 7-methylguanosine internal, m2,2G: N2,N2,-di-
methylguanosine, m2G: N2-methylguanosine, Q: queuosine, yW et al.: Wybutosine and derivatives, m5U: 5-methyluridine, ncm5U: 5-carbamoyl-methyluridine,
mcm5U: 5-methoxycarbonyl-methyluridine, mcm5s2U: 5-methoxycarbonylmethyl-2-thiouridine, D: dihydrouridine, Ψ: pseudouridine, Nm: 2′-O-Methylnucleotide,
m(pN): 5′ phosphate monomethylation, A-to-I: Deamination of Adenosine, C-to-U: Deamination of Cytosine. RNA modifying enzymes: ADAR1-3: Adenosine
Deaminase RNA Specific 1–3, ALKBH1/3/5/8: AlkB Homolog 1/3/5/8, APOBEC1/3G: Apolipoprotein B mRNA Editing Enzyme Catalytic Subunits 1/3G, BCDIN3D:
BCDIN3 Domain Containing RNA Methyltransferase, BUD23: RRNA Methyltransferase And Ribosome Maturation Factor, CDK5RAP1: CDK5 Regulatory Subunit
Associated Protein 1, CMTR1/2: Cap Methyltransferase 1/2, CTU1/2: Cytosolic Thiouridylase Subunit 1/2, DKC1: Dyskerin Pseudouridine Synthase 1, DNMT2: tRNA
Aspartic Acid Methyltransferase 1, DUS2: Dihydrouridine Synthases 2, ELP3: Elongator Acetyltransferase Complex Subunit 3, FTO: FTO Alpha-Ketoglutarate
Dependent Dioxygenase, HENMT1: HEN Methyltransferase 1, METTL1/2/3/6/8/14/16: Methyltransferase Like-1/2/3/6/8/16, NAT10: N-Acetyltransferase 10,
NSUN1-5: NOP2/Sun RNA Methyltransferase 1–5, NUDT16: Nudix Hydrolase 16, RNMT: RNA Guanine-7 Methyltransferase, TGT: Queuine TRNA-Ribosyltransferase
Catalytic Subunit 1, TRIT1: tRNA Isopentenyltransferase 1, TRMT1/2A/2B1/5/6/10C/11/61A/61B/112: tRNA Methyltransferase Subunits, TYW2: tRNA-YW
Synthesizing Protein 2 Homolog.
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translation initiation, and gene regulation. Thus, although the existence
of these modifications is well known, the mechanisms and functions of
many of them remain largely unknown. Dissecting the functions of RNA
modifications is challenging because RNA transcripts are diverse
(coding and noncoding), highly structured, relatively short-lived with
highly variable half-lives, located in several cellular compartments and
amplified through transcription (low- or high-abundance RNAs). Ac-
curate and precise methods are needed to detect and quantify them
alongside integrated multi-omics research for a better understanding of
their molecular mechanisms and roles. Hence, an exciting new era is
emerging to decode the epitranscriptome, a complex layer of RNAs
decorated with chemical marks (Fig. 1).
Alteration of RNA modification patterns is well-understood and is
associated with various human diseases such as cancer [12]. Table 1
compiles all the RNA modifications and RNA-modifying enzymes that
have, to date, been linked to cancer.
One of the most well-studied RNA modifications linked to cancer is
N6-methyladenosine (m6A). This modification is reversible and is the
most prevalent modified nucleotide found in eukaryotic mRNAs and in
low-abundance ncRNA (miRNA), affecting more than 7000 mRNAs in
mammalian cells and exerting many regulatory functions affecting RNA
metabolism; these include increasing turnover of mRNA through
binding to the reader YTHDF2 (Fig. 2B), promoting mRNA translation
through binding to YTHDF1, promoting exon inclusion during splicing
by binding to YTHDC1, promoting pri-miRNA processing by recruiting
hnRNPA2B1 and DGRC8, and regulating transcript nuclear export.
Many new functions of m6A are still being discovered. Depending on
the cancer cell type, m6A can promote or suppress tumorigenesis. On
the one hand, a high amount of m6A mark promotes the translation of
key oncogenic drivers such as MYC, retaining pluripotency attributes
and blocking cell differentiation in Acute Myeloid Leukemia (AML)
cells [23], but on the other hand, the low amount of m6A is also as-
sociated with oncogenic functions, downregulating the expression of
PHLPP2, a negative regulator of AKT, and thereby enhancing tumor-
igenesis in endometrial cancer cells [24]. Thus, the m6A role in cancer
progression depends entirely on the cell type and mRNA affected.
Another significant RNA modification is 5-methylcytosine (m5C),
which is present in many types of RNA, including mRNA, rRNA, tRNA
and other types of ncRNA. Similar to the m6A mark, m5C acts as an
oncogene and tumor suppressor. For example, the enrichment of the
methyl mark m5C in mRNAs of certain oncogenes promotes bladder
cancer progression through the stabilization of multiple mRNA tran-
scripts including HDGF and RAB11 [25]. More recently, it was reported
that the loss of m5C mark in the position C3782 of 28S rRNA leads to
glioblastoma progression by epigenetic silencing of NSUN5, associated
with depletion of global protein synthesis and a shift of the translational
profile to a more stress-resistant phenotype [26] (Figs. 2C and 3).
Inosine is the product of the enzymatic deamination of adenosine
and is a highly conserved RNA-editing mechanism that changes the
encoded information of RNA, since inosine preferentially pairs with
cytidine instead of thymine. This modification occurs only in double-
stranded regions of mRNA, tRNA, rRNA, and miRNAs. In mRNA, in-
osine can recode a protein-coding mRNA sequence and alter splice sites,
while in ncRNA, it alters nRNA structure and can thereby alter the
capacity to bind to other molecules. Impaired editing of key transcripts
can lead to certain types of cancer, in which highly edited NEIL1 and
miR-381 transcripts enhance the growth of the Non-Small-Cell Lung
Cancer (NSCLC) A459 cells [5].
An important number of RNA modifications related to cancer affect
the wobbling and dangling positions of tRNAs (bases 34 and 37, re-
spectively). These two positions can harbor many different types of
modifications, which facilitate the decoding of multiple synonymous
mRNA codons and restrict pairing with non-cognate codons. More
precisely, defects in tRNAs modifications at position 34 (queuosine,
mcm5s2U, m5C, and m3C), and position 37 (wybutosine and deriva-
tives, N6-isopentenyladenosine, and ms2i6A), are related with
translational shifts that may lead to cancer progression (summarized in
Table 1 and Fig. 2A).
There are many other types of RNA modifications related to cancer
progression. However, they are not all described in this review. In brief,
the deposition or removal of RNA modification in various RNA species
regulates a broad spectrum of RNA regulatory processes that results in
the regulation of a specific sets of genes. Thus, the molecular destiny of
any given RNA transcript is determined by the context of the RNA
molecule and the RNA effector enzymes in question. The crucial factors
that determine RNA modification metabolism are subcellular localiza-
tion of both RNAs and RNA-modifying proteins, the number of tran-
scripts of specific cellular RNAs, the various types of RNAs, the folding
and structure of RNAs, RNA-protein interactions, and responses to
stress stimuli such DNA and RNA damage [11]. Remarkably, defects in
any of these processes may lead to cancer progression.
3.2. RNA-modifying enzymes and their RNA modifications associated with
cancer
The number of RNA-modifying enzymes is steadily increasing and
accounts for about 350 enzymes (Modomics database) [22], opening up
new lines of research in the field of epitranscriptomics. Gene amplifi-
cations and mutations of RMPs have been reported in cancer [12],
demonstrating that alterations in these enzymes are associated with
tumor initiation and progression, metastasis, and cancer drug re-
sistance.
The examples of RNA-modifying enzymes implicated in cancer are
shown and listed in Table 1, containing the RNA modification enzymes
linked to a specific RNA chemical modifications and the related cancer
types. The most relevant findings of RNA-modifying enzymes are
summarized below with a special focus on “writers” and “erasers”.
The gene amplification of RNA-editing enzyme ADAR1 is associated
with lung [5], liver [27] and esophageal cancers [28], as well as chronic
myelogenous leukemia [29]. In particular, ADAR1 promotes lung
cancer through A-to-I editing of coding NEIL1 mRNA and non-coding
miRNA miR-381 [5].
As an example of RNA “writers” and “erasers”, it has been docu-
mented that the overexpression of the RNA-modifying enzymes FTO
[30], METTL3 [31], and NSUN2 [26 promotes pathogenesis through
stabilizing specific sets of mRNAs in breast cancer, AML, and bladder
cancer, respectively (Fig. 3). Furthermore, the loss of ALKBH5 [32] in
AML and METTL3 [33] and NSUN5 [26] in glioblastoma promotes
disease progression. Additionally, dysregulation of RNA readers also
has implications in cancer progression. For m6A readers, YTHDC2 has
been implicated in colorectal cancer and YTHDF2 dysregulation is re-
lated to pancreatic, hepatic, and prostate cancers (Table 1).
Paradoxically, some RNA-modifying enzymes might exhibit both
oncogenic and tumor suppressors functions. For instance, m6A me-
thyltransferase METTL3 was reported to have dual roles in cancer,
acting as an oncogene in AML, breast, and liver cancers, and as a tumor
suppressor in glioblastoma and endometrial cancers. Analogously,
ALKBH5 and TGT were identified to have similar dual roles as onco-
genes and tumor suppressors in different types of cancer, indicating that
the role of RNA-modifying enzymes is cell-type-specific and tissue-
context-dependent (see Fig. 2 and Table 1 for more details). Moreover,
some studies focused on understanding the role in cancer of m6A and its
associated enzymes have unexpectedly indicated that m6A may en-
hance oncogenesis, yet in other instances may inhibit cell proliferation
and transformation. In particular, METTL3 as methyltransferase of m6A
was identified as an oncogene in AML and demonstrated that the
overexpression of wild-type METTL3 inhibits cell differentiation and
increases cell growth through its ability to catalyze the deposition of
m6A and enhance the translational activation of C-MYC, BCL2 and
PTEN mRNA transcripts in AML cells [31]. However, another study
showed that m6A demethylase FTO [34] is highly expressed in certain
subtypes of AMLs and plays a critical oncogenic role in AML by
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Fig. 2. Landscape of tRNA, rRNA, and mRNA modifications associated with RNA modifications, and their respective RNA-modifying proteins associated with cancer.
A. Schematic representation of the tRNA molecule with the specific location and types of predominant RNA modifications and their respective RNA-modifying
proteins involved in cancer. B. mRNA. C. rRNA.
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reducing the amount of m6A in ASB2 and RARA mRNA transcripts.
Nevertheless, FTO activity as an m6A “eraser” is still a contentious
issue. Work led by Jaffrey has revealed that FTO preferentially de-
methylates m6Am (N6,2′-O-dimethyladenosine) present in 5′-caps of
mRNAs, rather than m6A [35]. Moreover, many m6A detection tech-
nologies inadvertently map m6Am modifications as m6A sites. Thus,
the concept of reversible m6A is still controversial, since the biological
role and evidence of its removal are not fully understood, adding a layer
of complexity when trying to associate m6A with cancer progression.
Overall, evidence accumulated to date reveals that the roles of RNA-
modifying enzymes differ between different cell subtypes, suggesting
that the depletion of m6A in different subtypes of AML induces cellular
differentiation and apoptosis [31], whereas in other subtypes of AML
m6a depletion upregulates oncogenes that promote cell proliferation
and suppress apoptosis [34]. Furthermore, recent discoveries empha-
size the importance of the different cellular and molecular contexts in
which RNA modifications are regulated. RNA-modifying enzymes
modulate RNA chemical marks at specific regions of any given RNA
molecule in a context-dependent manner, resulting in different cell fate
decisions and functional outcomes. First, subcellular localization of
enzymes modulates accessibility to substrates and substrate preference.
Second, localization and expression of RNA-modifying enzymes can be
regulated by their post-translational modifications, contributing to the
spatial regulation of the enzymes [36]. Third, the expression patterns of
some RNA-modifying enzymes differ between tissues and interact with
different protein interaction partners, resulting in the participation of
different signaling pathways. And fourth, the expression of a specific set
of RNAs could be modulated by environmental signals, hypoxia, nu-
trient levels, cytokine signaling, and in response to stimuli, DNA da-
mage [37], and stress. For more details, these findings have recently
been extensively reviewed in depth elsewhere [11].
Altogether, RNA-modifying enzymes linked to cancer are crucial
regulators of cell fate decisions and cell differentiation by regulating
RNA metabolism and expression of specific genes required for cell
proliferation, transformation, invasion, and cancer drug resistance. The
impact of RNA modifications and their enzymes affects almost every
aspect of RNA fate and is dependent on cell and tissue-type-specific
context, subcellular localization of the enzymes, responses to several
stimuli such as DNA damage, signal transduction pathways, and the
availability of energy sources, metabolic substrates, and oxygen.
Henceforth, recent cancer epitranscriptomics research is focused on
the complex cellular context and heterogeneity of RNA molecules and
cancer, in order to better understand the potential roles of RNA mod-
ifications and their enzymes and explore RNA-modifying enzymes as
potential anticancer drug targets.
4. Interplay between metabolism and epitranscriptomics in
cancer
The impairment of metabolic programs in cancer has remarkable
effects on epigenetic regulation, contributing to genomic instability.
Metabolites, cosubstrates, and cofactors such as iron, oxygen, ATP,
acetyl-CoA, SAM, and 2-oxoglutarate have a direct impact on the ac-
tivity of the epigenetic modification enzymes. These epigenetic en-
zymes that transfer methyl, acetyl, and other groups are involved in
chemical modifications that influence gene regulation, RNA metabo-
lism, and chromatin remodeling (Fig. 3).
Cancer cells metabolize glucose, lactate, pyruvate, and glutamine at
a higher rate than normal cells. In particular, many tumor cells exhibit
an altered Krebs or tricarboxylic acid (TCA) cycle, thereby causing an
accumulation of certain metabolites such as alpha-ketoglutarate (α-KG)
that increases the activity of the α-KG-dependent enzymes such as those
of the TET and ALKBH protein families. Thus, the metabolites affect the
cancer epigenetic landscape.
The metabolic reprogramming of tumor cells not only enables cells
to adapt to extreme environmental conditions such as stress and hy-
poxia, but also induces metabolic plasticity and heterogeneity by reg-
ulating gene expression, cellular differentiation, and the tumor
Fig. 3. Crosstalk between the epitranscriptome and metabolism in cancer initiation and progression. Epigenetic RNA modification pathways in cancer representing
the effect of RNA-modifying enzymes and their respective RNA modifications of the expression of genes involved in metabolism and tumorigenesis. Illustration of
RNA “writers” such as METTL3, NSUN2, NSUN5, and CTU1, and “erasers” such as FTO, ALKBH5, and ALKBH1.
R. Esteve-Puig, et al. Cancer Letters 474 (2020) 127–137
133
microenvironment. Crosstalk between the complex cancer-associated
metabolic reprogramming and cancer epigenetics and epitran-
scriptomics has a critical role in tumorigenesis and a deeper under-
standing of the metabolism and epitranscriptomics in cancer could
improve clinical outcomes in cancer treatment [12].
α-KG is an essential endogenous intermediary metabolite in the
Krebs cycle that regulates DNA “erasers” and histone modifiers as well
as RNA-modifying enzymes such as ALKBH family members (FTO and
ALKBH5) (Fig. 3).
R-2-hydroxyglutarate, also known as the oncometabolite R-2HG, is
accumulated at high concentrations by the mutant isocitrate dehy-
drogenases 1/2 (IDH1/2) in tumor cells such as gliomas of grade II-III,
secondary glioblastoma, and AML. Also, R-2HG is produced by other
enzymes and can cause metabolic alterations in cells lacking IDH mu-
tations. R-2HG and α-KG share a similar structure, resulting in R-2HG
binding to the same site place as α-KG. Thus, R-2HG acts as a compe-
titive inhibitor of α-KG, binding to the active sites of specific enzymes
such as α-KG-dependent dioxygenases. As previously discussed, m6A
“eraser” FTO, a homolog of the Fe(II) α-KG acid-dependent ALKBH
family dioxygenase, is overexpressed in AML. In particular, the FTO
demethylase plays a role as an oncogene, responsible for the de-
methylation of m6A on ASB2 and RARA mRNA transcripts and ulti-
mately promoting cell transformation and leukemogenesis [34]. It has
been documented that inhibition of the FTO demethylase by the on-
cometabolite R-2HG suppresses leukemia progression by stabilizing
MYC/CEBPA transcripts [38] (Fig. 3). Different findings indicate, on the
one hand, that R-2HG acts as an oncometabolite in certain subtypes of
cancer harboring IDH1/2 mutations and, on the other hand, that R-2HG
inhibits FTO and promotes antitumor effects. Again, these findings
demonstrate the importance of taking specific contextual factors into
consideration local contexts such as the type of enzyme, the subcellular
localization of the enzyme and the cell-type specific context.
To date, a total of 36 RNA methyltransferases have been identified
in humans, according to the MODOMICS database. These enzymes
catalyze methylation via a methyl synthase mechanism, using SAM as
the source and cofactor to methylate RNA molecules, and importantly,
they are a well-known broad group of “writers” involved in human
diseases such as cancer [12]. In particular, m6A “writer” METTL3 is the
best-characterized RNA methyltransferase enzyme associated with
cancer, regulating m6A in mRNAs of critical oncogenes and tumor
suppressors in a cell-type-specific manner. The majority of human RNA
methyltransferases (over 27 enzymes) are linked to cancer. Some ex-
amples are ALKBH8, BCDIN3D, BUD23, CDK5RAP1, DNMT2, ELP3,
Fibrillarin, HENMT1, MePCE, METTL1, 3, 6, 8 and 16, NSUN1-5,
RNMT, TRMT1, TRMT10C, 11, 2A, 6, 61A and 61B. METLL16 is an
informative example of an important class of SAM-dependent RNA
methyltransferases: METTL16 has been reported to interact with
cancer-associated lncRNA MALAT1 [39], which transcriptionally reg-
ulates the expression of MAT2A mRNA, which encodes the SAM syn-
thetase (Fig. 3). Under SAM-limiting conditions, METTL16 promotes
MAT2A splicing, indicating that cells control SAM homeostasis by
regulating SAM synthetase gene expression.
Hypoxia in cancer leads to the inhibition of biosynthetic reactions
that require oxygen, switching from oxidative phosphorylation to
anaerobic glycolysis, resulting in ER stress induction and apoptosis in
tumor cells. For example, it has been reported that the U34 enzymes
that catalyze modification of wobble uridine 34 tRNA promote glyco-
lysis, survival, and resistance to melanoma therapy through the main-
tenance of a high amount of HIF1-α protein [40]. In particular, U34
enzymes CTU1 and CTU2, play a central role in the 2-thiolation of
mcm5S2U modification on tRNA and were found to be upregulated in
BRAF mutant melanoma, conferring survival and drug resistance. In-
terestingly, NRAS mutant melanoma cells exhibited upregulation of
HIF1-α mRNA transcripts and were sensitive to the silencing of U34
enzymes, indicating that the dependence on U34 enzymes in melanoma
relies mostly on their metabolic status, rather than mutational status
(Fig. 3). In summary, RNA-modifying enzymes have been associated
with metabolic and translational reprogramming that ensures enhanced
glycolytic metabolism in cancer. Furthermore, the depletion of the
mcm5s2U “writers” (CTU1 and 2) resensitized drug-resistant melanoma
cells, indicating their potential as anticancer drug targets.
Taken together, RNA-modifying enzymes are susceptible to changes
in the concentrations of cosubstrates and cofactors such as SAM, 2-
oxoglutarate, ATP, and acetyl-CoA and are crucial regulators of RNA
and cell metabolism, thereby altering metabolic pathways such as
glycolysis, mitochondrial respiratory chain complex activity, and hy-
poxia (see examples above). In the past decade, it has been reported
that aberrant RNA modifications patterns and RNA-modifying enzymes
were involved in cancer initiation and progression, and also in drug
resistance. Thus, RNA modifications and RNA-modifying enzymes have
been demonstrated to affect multiple aspects of RNA metabolism and
function, resulting in altered cell fate and differentiation in response to
cellular signaling and environmental stimuli such as hypoxia, stress,
and DNA damage [41]. Regarding the latter, numerous DNA damaging
drugs such as the classical DNA-damaging chemotherapy, not only
damage and modify DNA, but also affect RNA, opening up a promising
new avenue for chemotherapy response prediction [18].
Although the emergent field of the development of epitran-
scriptomic drugs is still in its infancy, technological advancement has
been essential in significantly accelerating advances in our under-
standing of epitranscriptomics that have been made in recent years,
indicating that RNA-modifying enzymes may be considered as novel
druggable targets for cancer treatment. Therefore, it is crucial to in-
vestigate the molecular mechanisms and the roles of RNA modifications
and RNA-modifying enzymes in the appropriate cellular contexts in
order to better leverage advances in cancer treatment.
5. Discussion
5.1. Challenges in mapping RNA modifications and emerging applications
Decoding the complex layer of the epitranscriptome has, up to now,
been very challenging. Recent technological advances have, in the past
decade, enabled mapping of certain RNA modifications such as m6A
and pseudouridine. For instance, the pioneering detection of the m6A
modification was done by antibody-based Next Generation Sequencing,
which allows the capture and sequencing of immunoprecipitated RNA
targets [42]. Some mapping approaches presented several limitations
such as false-positive mapping results, lack of detection of low-abun-
dance modifications, possible contaminations of RNA species, low an-
tibody specificity, and Dimroth rearrangement (conversion of m1A to
m6A). Currently, the major challenges are the quantification of RNA
modifications directly at modification sites with higher resolution,
precision, and sensitivity as well as improving our understanding of the
molecular mechanisms and functional roles of RNA modifications and
RNA-modifying enzymes. However, technology is rapidly progressing
and novel methodologies for more precise and sensitive detection,
imaging and quantification of RNA modifications are emerging, such as
deamination adjacent to RNA modification targets (DART-seq), phage
display antibody technology and direct sequencing through nanopores
[12] (third-generation sequencing technologies), and fluorescent nu-
cleobases [43] will enable the global detection and determination of
stoichiometries of RNA modifications, even for RNA modifications at
very low stoichiometries, as well as the study of concomitant and
combinatorial RNA modification profiles.
5.2. Clinical oncology impact
One of the major discoveries made in the field of epitranscriptomics
with regard to their clinical implications is the identification of mRNA
and noncoding RNA modifications linked to human diseases including,
but not limited to metabolic and neurological diseases and cancer.
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The interplay between complex cancer-associated metabolic repro-
gramming and cancer epigenetics and epitranscriptomics has a critical
role in tumorigenesis. A deeper understanding of the crosstalk between
metabolism and epitransciptomics in cancer is necessary to elucidate
the roles of RNA modifications and RNA-modifying enzymes and to
understand their contributions in this disease.
In the past 20 years, it has been documented that DNA methylation,
histone modification, nucleosome remodeling, and noncoding RNAs are
important for biological processes, regulating cell differentiation, divi-
sion, and development. For example, post-translational modifications of
proteins and chromatin modifications are frequently dysregulated in
cancer and have been used as successful epigenetic drug targets. In line
with this, RNA-modifying enzymes as regulators of RNA metabolism
and gene expression indicate that targeting RNA-modifying enzymes
could also be a promising therapeutic strategy to improve cancer
treatment and patient outcomes. Furthermore, new research works
have very recently appeared in the literature that link the inhibition of
certain RMPs, such as “reader” YTHDF1 [44] and RNA-editing enzyme
ADAR1 [45], with a better response to immunotherapeutic agents.
Thus, RNA-modifying proteins may be important for cancer drug dis-
covery as emerging anticancer drug targets.
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